Kishiwada Tokushukai Hospital > Neurology > Alzheimer’s-related Testing

Alzheimer’s-related Testing

What we do
Diagnostic evaluation for suspected Alzheimer’s disease, including amyloid PET when appropriate

Purpose
Clarify diagnosis and support treatment planning

Next steps
Follow-up care or referral based on clinical findings

We evaluate patients with early memory symptoms or suspected mild cognitive impairment (MCI).
When clinically appropriate, amyloid PET may be used to support diagnosis and guide further management,
including consideration of disease-modifying treatment.

Who may benefit from evaluation

  • Progressive memory decline affecting daily life
  • Suspected MCI due to Alzheimer’s disease
  • Unclear diagnosis after standard assessment
  • Planning treatment options that require confirmation of amyloid pathology
  • Referral for further evaluation, including possible amyloid PET

Amyloid PET is not used for general screening or routine health checkups.
It is considered only when clinically appropriate.

What amyloid PET can show

Amyloid PET is an imaging test that detects amyloid plaque deposition,
which may be associated with Alzheimer’s disease.
It is used as part of a broader clinical assessment.

  • Indicates whether amyloid pathology is present
  • Supports decisions about treatment options
  • Does not determine symptom severity or daily function on its own
  • Does not replace clinical evaluation, cognitive testing, or MRI

Results are interpreted together with symptoms, examination findings, and other tests.

Before testing

Before considering amyloid PET, we carry out a structured assessment.
This includes review of symptoms, cognitive testing, and evaluation of prior imaging and medical records.

The aim is to ensure that testing is appropriate and will contribute to clinical decision-making.

After testing

After testing, we explain the results and discuss next steps.
This may include follow-up care, medication review, lifestyle advice, and coordination with family where appropriate.

If findings are consistent with early Alzheimer’s disease and safety criteria are met,
we may proceed to evaluation for treatment options such as
Lecanemab (Leqembi®) or Donanemab (Kisunla®).

Appointment

Appointments are required in principle. A referral letter from another medical institution is recommended but not mandatory.
Amyloid PET is arranged only after specialist evaluation and scheduling.

Please bring any relevant records if available (prior cognitive test results, MRI/CT reports, medication list).
If possible, a family member should accompany the patient.

For appointment requests and language support, please see the
Neurology page.